Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries. This paper argues that European Union trade policies should not be used to bolster pharmaceutical companies’ profits by extending their monopolies on medicine prices to supposedly reward research. Instead, the incoming […]
